What's Going On With Crispr Therapeutics Stock Thursday?
Portfolio Pulse from Adam Eckert
CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc (NASDAQ:VRTX) announced that the UK MHRA granted conditional marketing authorization for their CRISPR/Cas9 gene-edited therapy, CASGEVY, for sickle cell disease treatment. This marks the first regulatory authorization of a CRISPR-based therapy. CRISPR Therapeutics' stock rose 4.93% to $59 following the news.
November 16, 2023 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics' stock increased after the announcement of the UK MHRA authorization for CASGEVY, a gene-edited therapy for sickle cell disease.
The positive regulatory news directly impacts CRISPR Therapeutics as it opens up a new market for their therapy, potentially increasing revenue and investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Vertex Pharmaceuticals, in partnership with CRISPR Therapeutics, received UK MHRA authorization for their joint gene-edited therapy, which could positively impact Vertex's stock.
Vertex Pharmaceuticals, being a partner in the development of CASGEVY, is likely to experience a positive stock movement due to the potential for increased future revenues and the historic nature of the approval.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80